Order Article Reprints

van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, et al. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers. 2024; 16(8):1448. https://doi.org/10.3390/cancers16081448

van Dijk, Anneke D., Fieke W. Hoff, Yihua Qiu, Stefan E. Hubner, Robin L. Go, Vivian R. Ruvolo, Amanda R. Leonti, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, and et al. 2024. "Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial" Cancers 16, no. 8: 1448. https://doi.org/10.3390/cancers16081448

van Dijk, A. D., Hoff, F. W., Qiu, Y., Hubner, S. E., Go, R. L., Ruvolo, V. R., Leonti, A. R., Gerbing, R. B., Gamis, A. S., Aplenc, R., Kolb, E. A., Alonzo, T. A., Meshinchi, S., de Bont, E. S. J. M., Horton, T. M., & Kornblau, S. M. (2024). Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers, 16(8), 1448. https://doi.org/10.3390/cancers16081448